Bristol-Myers cancer drug Opdivo fails to meet a primary endpoint in phase 3 trialMarket Watch • 09/05/19
What Investors Need to Know About the Celgene, Amgen & Bristol-Myers DealsZacks Investment Research • 08/28/19